S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Chimerix Stock Forecast, Price & News

-0.08 (-1.30 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume572,468 shs
Average Volume872,985 shs
Market Capitalization$525.26 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Chimerix logo

About Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.


Chimerix (NASDAQ:CMRX) Trading 6.4% Higher
October 11, 2021 |  americanbankingnews.com
David Jakeman Sells 4,590 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock
September 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$5.37 million
Book Value
$1.17 per share


Net Income
$-43.52 million
Net Margins




Market Cap
$525.26 million
Next Earnings Date
11/4/2021 (Estimated)


Overall MarketRank

2.04 out of 5 stars

Medical Sector

531st out of 1,361 stocks

Pharmaceutical Preparations Industry

246th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

Is Chimerix a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix
or view top-rated stocks.

What stocks does MarketBeat like better than Chimerix?

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chimerix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Chimerix?

Chimerix saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 2,480,000 shares, a drop of 15.4% from the August 31st total of 2,930,000 shares. Based on an average daily trading volume, of 721,500 shares, the days-to-cover ratio is currently 3.4 days. Currently, 3.2% of the shares of the stock are short sold.
View Chimerix's Short Interest

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chimerix

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biopharmaceutical company had revenue of $0.39 million for the quarter. Chimerix had a negative trailing twelve-month return on equity of 54.11% and a negative net margin of 3,035.43%.
View Chimerix's earnings history

How has Chimerix's stock price been impacted by Coronavirus (COVID-19)?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 322.9% and is now trading at $6.09.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CMRX?

5 analysts have issued 12 month price targets for Chimerix's stock. Their forecasts range from $14.00 to $21.00. On average, they expect Chimerix's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 212.0% from the stock's current price.
View analysts' price targets for Chimerix
or view top-rated stocks among Wall Street analysts.

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Michael A. Sherman, President, Chief Executive Officer & Director
  • Michael T. Andriole, Chief Financial & Business Officer
  • Randall Lanier, Chief Scientific Officer
  • Roy W. Ware, Chief Technology & Manufacturing Officer
  • Caryn Barnett, Vice President-Clinical Operations

What other stocks do shareholders of Chimerix own?

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $6.09.

How much money does Chimerix make?

Chimerix has a market capitalization of $525.26 million and generates $5.37 million in revenue each year. The biopharmaceutical company earns $-43.52 million in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Chimerix have?

Chimerix employs 54 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

Where are Chimerix's headquarters?

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at (919) 806-1074 or via email at [email protected].

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.